Bacil Pharma FY26 Net Loss of ₹61.88 Lakhs

Board Meeting Details

The Board of Directors meeting was held on Friday, 22nd May 2026, commencing at 05:00 PM and concluding at 08:00 PM. The Board discussed and approved:

Approval of the Audited Financial results for the quarter and year ended 31st March, 2026
Review of other business activities

Financial Results Overview

Balance Sheet as at 31st March, 2026 (Rupees in Lacs)

Assets:

Non-current assets: ₹2,504.99 (Previous year: ₹2,800.92)
Investments: ₹2,424.00 (Previous: ₹2,135.66)
Loans: ₹78.10 (Previous: ₹128.26)
Deferred tax assets (net): ₹61.89 (Previous: ₹536.00)
Current assets: ₹234.27 (Previous: ₹-240.90)
Trade receivables: ₹118.00 (Previous: ₹0.00)
Cash and cash equivalents: ₹56.85 (Previous: ₹285.73)
Other current assets: ₹0.45 (Previous: ₹5.02)
Total Assets: ₹2,739.26 (Previous: ₹2,560.02)

Equity and Liabilities:

Equity: ₹2,481.26 (Previous: ₹2,543.14)
Equity Share capital: ₹1,397.02 (Previous: ₹1,397.02)
Other Equity: ₹1,084.24 (Previous: ₹1,146.12)
Current liabilities: ₹258.06 (Previous: ₹16.88)
Borrowings: ₹0.00 (Previous: ₹16.39)
Trade Payables: ₹1.97 (Previous: ₹0.41)
Other Financial Liabilities: ₹18.00 (Previous: ₹0.00)
Other current liabilities: ₹0.00 (Previous: ₹0.09)
Provisions: ₹238.06 (Previous: ₹0.00)
Total Equity and Liabilities: ₹2,739.27 (Previous: ₹2,560.02)

Financial Performance (Rupees in Lacs)

| Revenue from operations | - | - | - | 198.50 |

| Other income | 11.34 | 6.45 | 66.14 | 123.52 |

| Total revenue | 11.34 | 6.45 | 66.14 | 322.02 |

| Total expenses | 7.45 | 2.53 | 25.38 | 204.68 |

| Profit/(Loss) before tax | 3.89 | 3.92 | 40.76 | (6.17) |

| Tax expense: Deferred tax | 58.97 | - | 56.53 | - |

| Profit/(Loss) after tax | (62.16) | 3.92 | (15.55) | (6.17) |

| Other Comprehensive Income | (226.30) | 2.18 | (217.43) | - |

| Profit/(Loss) for the Period | (164.14) | 6.10 | (232.98) | (6.17) |

Key Metrics:

Paid up Equity Share Capital: ₹1,397.02 lacs (Face Value of ₹10 each)
Earnings Per Share (EPS) for Q4 FY26:
Basic: (₹0.44)
Diluted: (₹0.44)
EPS for FY26: Not annualized

Cash Flow Statement (Rupees in Lacs)

Cash generated from operations: ₹71.16
Net cash from operating activities: ₹71.16 (after direct taxes paid net of refunds)
Net cash used in investing activities: ₹(238.16)
Net cash from financing activities: ₹6,188.00
Net increase in cash and cash equivalents: ₹22,888.00
Cash and cash equivalents at beginning of year: ₹28,573.00

Additional Information

The company has a single business segment
Previous quarter figures have been regrouped/reclassified where necessary
The company primarily engages in investment activities with minimal operational business
Investments stood at ₹2,424.00 lacs as of March 31, 2026
Loans granted during the year: ₹78.33 lacs, with outstanding balance of ₹72.56 lacs
No inventory maintained during the year
No defaults in repayment of dues to financial institutions or banks